Neuro-Bio Ltd. logo

Neuro-Bio Ltd.

Neuro-Bio is a privately held biotech company focussed on development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimers, Parkinsons and Motor Neuron Diseases.

Neuro-Bio is validating the theory of its founding scientist, Susan Greenfield, which holds that, a peptide derived from the enzyme acetylcholinesterase (AChE) acts as a toxin and initiates a cycle of cell death and neurodegeneration in the adult brain.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.neuro-bio.com
Disease Focus
STOCK CODENon Listed
Address
Building F5 Culham Science Centre, OX14 3DB
Abingdon
United Kingdom
Email
Contact Number
+44 1235 420085

Neuro-Bio is a privately held biotech company focussed on development of novel, effective therapeutics for neurodegenerative disorders such as Alzheimers, Parkinsons and Motor Neuron Diseases.

Neuro-Bio is validating the theory of its founding scientist, Susan Greenfield, which holds that, a peptide derived from the enzyme acetylcholinesterase (AChE) acts as a toxin and initiates a cycle of cell death and neurodegeneration in the adult brain.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/neuro-bio-limited” connections=”true” suffix=””]

The company has developed a method of intercepting and halting the action of the toxic AChE peptide on the receptor to arrest further cell death which is the major effect of many neurodegenerative disease.

In March 2017, Neuro-Bio Attracts Over $3 Million in Series A Investment to Develop a New Approach to Alzheimers Disease from US-based Kairos Ventures.